Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
GlaxoSmithKline
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT01397591
First received: July 13, 2011
Last updated: February 20, 2013
Last verified: October 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)